You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 69 No. 1, January 2012 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Original Article
 •Online Features
 This Article
 •Full text
 •PDF
 •eSupplement
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Functional Imaging
 •Psychiatry
 •Psychiatry, Other
 •Radiologic Imaging
 •Magnetic Resonance Imaging
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Induction of Psychosis by {Delta}9-Tetrahydrocannabinol Reflects Modulation of Prefrontal and Striatal Function During Attentional Salience Processing

Sagnik Bhattacharyya, MBBS, MD, PhD; José Alexandre Crippa, MD, PhD; Paul Allen, PhD; Rocio Martin-Santos, MD, PhD; Stefan Borgwardt, PhD; Paolo Fusar-Poli, MD; Katya Rubia, PhD; Joseph Kambeitz, MB; Colin O’Carroll, PhD; Marc L. Seal, PhD; Vincent Giampietro, PhD; Michael Brammer, PhD; Antonio Waldo Zuardi, MD, PhD; Zerrin Atakan, MD, FRCPsych; Philip K. McGuire, MD, PhD

Arch Gen Psychiatry. 2012;69(1):27-36. doi:10.1001/archgenpsychiatry.2011.161

Context  The aberrant processing of salience is thought to be a fundamental factor underlying psychosis. Cannabis can induce acute psychotic symptoms, and its chronic use may increase the risk of schizophrenia. We investigated whether its psychotic effects are mediated through an influence on attentional salience processing.

Objective  To examine the effects of {Delta}9-tetrahydrocannabinol ({Delta}9-THC) and cannabidiol (CBD) on regional brain function during salience processing.

Design  Volunteers were studied using event-related functional magnetic resonance imaging on 3 occasions after administration of {Delta}9-THC, CBD, or placebo while performing a visual oddball detection paradigm that involved allocation of attention to infrequent (oddball) stimuli within a string of frequent (standard) stimuli.

Setting  University center.

Participants  Fifteen healthy men with minimal previous cannabis use.

Main Outcome Measures  Symptom ratings, task performance, and regional brain activation.

Results  During the processing of oddball stimuli, relative to placebo, {Delta}9-THC attenuated activation in the right caudate but augmented it in the right prefrontal cortex. {Delta}9-Tetrahydrocannabinol also reduced the response latency to standard relative to oddball stimuli. The effect of {Delta}9-THC in the right caudate was negatively correlated with the severity of the psychotic symptoms it induced and its effect on response latency. The effects of CBD on task-related activation were in the opposite direction of those of {Delta}9-THC; relative to placebo, CBD augmented left caudate and hippocampal activation but attenuated right prefrontal activation.

Conclusions  {Delta}9-Tetrahydrocannabinol and CBD differentially modulate prefrontal, striatal, and hippocampal function during attentional salience processing. These effects may contribute to the effects of cannabis on psychotic symptoms and on the risk of psychotic disorders.


Author Affiliations: Departments of Psychosis Studies (Drs Bhattacharyya, Allen, Martin-Santos, Borgwardt, Fusar-Poli, Kambeitz, Atakan, and McGuire), Child & Adolescent Psychiatry (Dr Rubia), and Neuroimaging (Drs Giampietro and Brammer), Institute of Psychiatry, King's College London, London, England; Department of Neurology, Psychiatry, and Medical Psychology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil (Drs Crippa and Zuardi); Psychiatric Department, Institute of Neuroscience, Hospital Clinico, Institut d’investigacions Biomediques August Pi i Sunyer (IDIBAPS), Centro de investigacion Biomedica En Red de Salud Mental (CIBERSAM), Barcelona, Spain (Dr Martin-Santos); Psychiatric Outpatient Department, University of Basel, Basel, Switzerland (Dr Borgwardt); Dart Neuroscience LLC, San Diego, California (Dr O’Carroll); and Murdoch Childrens Research Institute, Melbourne, Australia (Dr Seal).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2012 American Medical Association. All Rights Reserved.